[
    [
        {
            "time": "",
            "original_text": "医药生物行业深度报告：CDMO行业进入黄金发展阶段 龙头企业竞争优势凸显",
            "features": {
                "keywords": [
                    "医药生物",
                    "CDMO",
                    "黄金发展",
                    "龙头企业",
                    "竞争优势"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业深度报告：CDMO行业进入黄金发展阶段 龙头企业竞争优势凸显",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "南向资金高比例持有港股名单",
            "features": {
                "keywords": [
                    "南向资金",
                    "港股",
                    "高比例持有"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "南向资金高比例持有港股名单",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业：第二款国产新冠疫苗获批上市 看好疫苗大时代背景下的新冠增量",
            "features": {
                "keywords": [
                    "医药生物",
                    "新冠疫苗",
                    "获批上市",
                    "增量"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业：第二款国产新冠疫苗获批上市 看好疫苗大时代背景下的新冠增量",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]